Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says - Novo Nordisk Shares Surge on New Obesity Drug Results - Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs - Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy - Novo Nordisk Earnings: Surge in Obesity Treatments Boosts Outlook - Obesity drug sales surge at Novo Nordisk - FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use - Novo Nordisk Shares Still Have a Long Road Back from 40% Slump - Novo Nordisk shares jump up on latest weight-loss drug trial results - Stocks making the biggest moves premarket: Twilio, Boeing, Novo Nordisk, CSX and more